Novel agents and new therapeutic approaches for treatment of multiple myeloma

doi:10.5662/wjm.v4.i2.73

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7303)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

433

WORD

352

HTML

3907

Figures (1-3)

228

Tables (1-4)

171

Sum=5091

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1017

Download

1195

Sum=2212

Jun 26, 2014 (publication date) through Jul 31, 2024

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Methodol. Jun 26, 2014; 4(2): 73-90
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.73

Table 4 Monoclonal antibodies evaluated in multiple myeloma therapy[147]

Monoclonal antibodies targeting tumor cells specific antigens
Antigen	MoAb
CD20	Rituximab, Tositumomab, 20-C2-2b Veltuzumab
CS1	Elotuzumab
CD138	B-B4, BC/B-B4, DL-101, 1D4, 1.BB.210, MI15, 2Q1484, 5F7, 104-9, 281-2, nBT062-SMCL-DM1, BT062-SPDM4, nBT062-SPP-DM1
CD38	Doratumumab, MOR202
CD40	Lucatuzumab, Lorvotuzumab
IGF-1	AVE1642, AMG479 IMCA12, R15507, Figitumumab, Dalotuzumab
CD317	AHM, Defucosylated AHM, XmAb 5592
CD48	Anti-CD48 MoAb
b2 m	IgG anti-b2m, IgM anti-b2m
CD70	SGN-70
CD74	Milatuzumab
HLADR	ID09C3, 2D7-DB
CD229	Anti-CD229
GM2 ganglioside	BIW-8962
ICAM-1	BI-505
Ku	5E2
Monoclonal antibodies targeting components of bone marrow microenvironment and plasma cellr–bone marrow stromalcell interaction
IL-6	Siltuximab, Tocilizumab, NRI, Elsilimomab, Azintrel, SANT-7
VEGF	Bevacizumab
EGFR	Cetuximab
FGFR-3	MFGR1877A
RANKL	Denosumab
Dickkopf	Anti-DKK1, BrlQ880
Activin	RAP-011, ACE-011
BAFF	Atacicept, SG1
Other potential targets
TRAIL-R1	Mapatuzumab
TRAIL-R2	Lexatuzumab
PD-L1	CD-011
VLA-4	Natalizumab
Kininogen	C11C1

Citation: Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2): 73-90
URL: https://www.wjgnet.com/2222-0682/full/v4/i2/73.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i2.73